Aybintio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
II/0016 
B.I.a.2.c - Changes in the manufacturing process of 
09/03/2023 
n/a 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/02/2023 
09/03/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
13/10/2022 
09/12/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02202 
bevacizumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/403/202202. 
IB/0015/G 
This was an application for a group of variations. 
21/07/2022 
09/12/2022 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0014 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
08/06/2022 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0012 
B.I.b.2.e - Change in test procedure for AS or 
12/05/2022 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or addition) for the AS or a starting 
material/intermediate 
IB/0011 
B.I.b.1.z - Change in the specification parameters 
28/01/2022 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
II/0009 
Amendments to the marketing authorisation 
28/10/2021 
n/a 
The table in Module 8b of the EPAR will be updated as 
The variation leads to no amendments to the terms 
of the Community Marketing Authorisation. 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
follows: 
Scope 
Please refer to the Recommendations section above  
Summary 
Not applicable 
IB/0010 
B.I.a.2.a - Changes in the manufacturing process of 
27/10/2021 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/403/2
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
02102 
bevacizumab 
N/0008 
Minor change in labelling or package leaflet not 
01/06/2021 
18/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
WS/2040/G 
This was an application for a group of variations 
06/05/2021 
18/11/2021 
SmPC and PL 
following a worksharing procedure according to 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0006 
B.II.d.2.a - Change in test procedure for the finished 
22/04/2021 
n/a 
product - Minor changes to an approved test 
procedure 
IAIN/0005/G 
This was an application for a group of variations. 
15/04/2021 
18/11/2021 
Annex II and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
IAIN/0003 
B.II.b.2.c.1 - Change to importer, batch release 
29/01/2021 
18/11/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
N/0002 
Minor change in labelling or package leaflet not 
25/01/2021 
18/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0001/G 
This was an application for a group of variations. 
18/11/2020 
18/11/2021 
SmPC and PL 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
